Plasma membrane lipid bilayer of cancer cells

The plasma membrane lipid bilayer of cancer cells serves as a critical interface between the malignant cell and its environment, characterized by distinct biochemical alterations compared to healthy cells (Riedl et al., 2011, Chemistry and Physics of Lipids). Key differences include the externalization of phosphatidylserine, which imparts a net negative charge to the outer leaflet, and changes in cholesterol and fatty acid composition that influence membrane fluidity and permeability (Gaspar et al., 2013, Frontiers in Physiology). These unique features allow the membrane to function as a selective therapeutic target for agents such as anticancer peptides and alkylphosphocholines (van Blitterswijk & Verheij, 2013, Cancer Metastasis Reviews). Drugs targeting this structure typically act by inducing membrane lysis, forming pores, or modulating lipid-mediated signaling pathways like the PI3K/Akt/mTOR axis to trigger apoptosis (Escribá et al., 2015, Progress in Lipid Research). However, achieving high selectivity remains a challenge, as off-target disruption of normal cell membranes can lead to side effects such as hemolysis (Hoskin & Ramamoorthy, 2008, Biochimica et Biophysica Acta). This target is central to the emerging field of membrane lipid therapy, which seeks to exploit the biophysical properties of the bilayer to treat various malignancies.

Other names

Cancer cell membraneTumor cell lipid bilayerNeoplastic cell membraneMalignant cell membrane

Drugs targeting the cancer cell lipid bilayer primarily act through membrane permeabilization, pore formation, or the modulation of lipid-dependent signaling pathways. Some agents exploit the negative charge of cancer membranes to induce selective lysis, while others alter membrane fluidity or interfere with the recruitment of signaling proteins to lipid rafts, ultimately triggering programmed cell death.